- Report
- February 2024
- 106 Pages
Global
From €4588EUR$4,750USD£3,926GBP
- Report
- October 2023
- 138 Pages
Asia Pacific
From €4250EUR$4,400USD£3,637GBP
- Report
- October 2023
- 133 Pages
Europe
From €4250EUR$4,400USD£3,637GBP
- Report
- January 2024
- 200 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- April 2024
Global
From €5747EUR$5,950USD£4,918GBP
- Report
- April 2024
Global
From €6278EUR$6,500USD£5,372GBP
- Report
- February 2024
- 100 Pages
Global
From €4588EUR$4,750USD£3,926GBP
- Report
- February 2024
- 150 Pages
Global
From €4588EUR$4,750USD£3,926GBP
- Report
- February 2024
- 176 Pages
Global
From €4588EUR$4,750USD£3,926GBP
- Report
- February 2024
- 120 Pages
Global
From €4588EUR$4,750USD£3,926GBP
- Drug Pipelines
- April 2024
- 100 Pages
Global
From €2897EUR$3,000USD£2,479GBP
- Report
- February 2024
- 150 Pages
Global
From €4105EUR$4,250USD£3,513GBP
- Report
- August 2023
- 145 Pages
Global
From €3042EUR$3,150USD£2,603GBP
- Report
- November 2023
- 144 Pages
Global
From €4298EUR$4,450USD£3,678GBP
- Report
- January 2024
- 250 Pages
Global
€4824EUR$4,995USD£4,128GBP
- Report
- August 2023
- 1300 Pages
Global
From €8596EUR$8,900USD£7,356GBP
- Report
- November 2023
- 190 Pages
Global
From €4781EUR$4,950USD£4,091GBP
- Report
- November 2023
- 110 Pages
Global
From €2849EUR$2,950USD£2,438GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4588EUR$4,750USD£3,926GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4588EUR$4,750USD£3,926GBP
Insulin Glargine is a long-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. It is administered by subcutaneous injection and works by helping the body use glucose more efficiently. Insulin Glargine is a recombinant human insulin analog that is modified to reduce its solubility and prolong its action. It is available in both prefilled pens and vials.
Insulin Glargine is a key drug in the Endocrine and Metabolic Disorders Drugs market. It is used to treat diabetes, a chronic condition that affects millions of people worldwide. It is an important part of diabetes management, helping to control blood sugar levels and reduce the risk of complications.
Companies in the Insulin Glargine market include Sanofi, Eli Lilly, Novo Nordisk, Merck, and Boehringer Ingelheim. Show Less Read more